CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Rockwell Medical, Inc. - RMTI CFD

1.87
1.08%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.85
Open 1.79
1-Year Change -48.27%
Day's Range 1.79 - 1.93
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 26, 2024 1.87 0.08 4.47% 1.79 1.93 1.79
Jul 25, 2024 1.82 -0.01 -0.55% 1.83 1.88 1.79
Jul 24, 2024 1.86 -0.02 -1.06% 1.88 1.90 1.81
Jul 23, 2024 1.92 0.02 1.05% 1.90 1.94 1.84
Jul 22, 2024 1.91 0.05 2.69% 1.86 1.95 1.86
Jul 19, 2024 1.89 0.03 1.61% 1.86 1.93 1.86
Jul 18, 2024 1.87 -0.04 -2.09% 1.91 1.99 1.84
Jul 17, 2024 1.99 0.01 0.51% 1.98 2.03 1.89
Jul 16, 2024 2.03 -0.06 -2.87% 2.09 2.11 1.97
Jul 15, 2024 2.12 0.04 1.92% 2.08 2.13 2.00
Jul 12, 2024 2.07 -0.14 -6.33% 2.21 2.24 2.03
Jul 11, 2024 2.07 0.11 5.61% 1.96 2.15 1.94
Jul 10, 2024 1.91 0.11 6.11% 1.80 1.98 1.76
Jul 9, 2024 1.79 0.03 1.70% 1.76 1.86 1.73
Jul 8, 2024 1.80 0.11 6.51% 1.69 1.80 1.69
Jul 5, 2024 1.68 -0.03 -1.75% 1.71 1.71 1.64
Jul 3, 2024 1.73 0.10 6.13% 1.63 1.74 1.63
Jul 2, 2024 1.67 0.02 1.21% 1.65 1.68 1.63
Jul 1, 2024 1.65 -0.04 -2.37% 1.69 1.74 1.65
Jun 28, 2024 1.72 0.01 0.58% 1.71 1.72 1.63

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Rockwell Medical, Inc. Company profile

About Rockwell Medical Inc

Rockwell Medical, Inc. is a commercial-stage, biopharmaceutical company. The Company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Rockwell Medical Inc revenues decreased 1% to $46.6M. Net loss increased 7% to $23.7M. Revenues reflect United States segment decrease of 1% to $41.9M. Higher net loss reflects Research and Product Development increase of 5% to $5.4M (expense), Interest Income decrease of 92% to $18K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.32 to -$0.25.

Equity composition

Common Stock no Par, 04/11, N/A auth., 17,843,608 issd. Insiders control 14.55%. IPO:1/98,1.8M Common @ $4 + 2.7M Warrants @ $.10 by Mason Hill & Co., Inc. *NOTE: FY'96 = 2 months due to 10/25/96 inception. All financials prior to 2/19/97 are Predecessor.

Industry: Bio Therapeutic Drugs

30142 Wixom Road
48393

People also watch

BTC/USD

67,899.75 Price
+3.940% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

ETH/USD

3,255.79 Price
+3.270% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,029.00 Price
+1.080% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.60 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading